Learn more Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer ...

May 29 (Reuters) - China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...

Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

The biologics CDMO market offers significant prospects driven by rising chronic disease prevalence, demand for targeted ...

Pharmaceutical products must be produced in a way that guarantees their efficacy and safety. For parenteral drug products, visual inspection (VI) is an essential quality control measure used to detect ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian ...